What is it?
Why is it best?
- Makes the body slenderer and the figure more beautiful
- Effectively reduces cellulite problems
- Cleanses the body of waste substances and repairs blood and lymphatic circulation
- Makes the skin smoother, more elastic, softer and revitalises dry skin
- Reduces muscular and joint pains
MK-677 (Ibutamoren) – Research Compound
MK-677, also known as Ibutamoren, is an investigational growth hormone secretagogue that has been studied for its interaction with the ghrelin receptor (GHSR-1a). In research settings, MK-677 is examined for its ability to stimulate the body’s natural release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Due to its oral bioavailability and long half-life, it has been a subject of interest in various preclinical and clinical investigations.
At Alfa Sports USA, MK-677 is manufactured and handled under strict quality-control procedures to support laboratory research applications. Each batch is processed using controlled production standards and undergoes analytical verification to ensure identity, purity, and consistency. Documentation is maintained to meet research material handling requirements.
MK-677 remains an investigational compound and is not approved by the FDA or other major regulatory authorities for human consumption. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for in-vitro research and analytical purposes only and is not sold as a dietary supplement, pharmaceutical product, or for use in food or animal applications.
Researchers studying MK-677 often focus on endocrine pathways, metabolic signaling, and growth hormone mechanisms. Proper laboratory protocols, compliance with local regulations, and responsible handling procedures are essential when working with this compound.
Alfa Sports USA is committed to responsible distribution practices, transparency, and maintaining high standards for research material quality.
For laboratory research purposes only. Not for human or veterinary use.


Recent Comments